High cure rate with 24 weeks of daclatasvir-based quadruple therapy in treatment-experienced null-responder HIV/HCV genotype 1/4 co-infected patients: the ANRS HC 30 QUADRIH study.

Date publication

mai 2015

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre

Tous les auteurs :
Piroth L, Paniez H, Taburet AM, Vincent C, Rosenthal E, Lacombe K, Billaud E, Rey D, Zucman D, Bailly F, Bronowicki JP, Simony M, Diallo A, Izopet J, Aboulker JP, Meyer L, Molina JM

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/25977266

Résumé

BACKGROUND: Few direct anti-HCV agents have been studied in difficult-to-treat, null responders and cirrhotic HIV co-infected patients. Daclatasvir and asunaprevir combined with pegylated interferon-ribavirin (PR) have shown promising results in HCV mono-infected patients. METHODS: An open-label, single-arm, phase-2 study was conducted in HIV/HCV genotype 1/4 co-infected patients, null responders to prior PR standard therapy, on a raltegravir-based regimen with HIV RNA

Référence

Clin Infect Dis. 2015 May 14. pii: civ381.